BCL2 and leukemia: While lymphoid malignancies nearly universally overexpress BCL-2 (Stilgenbauer et al., 2016; Ashkenazi et al., 2017), in myeloid leukemias, BCL-2 expression is heterogeneous and not always upregulated, with relapses showing higher percentages of positive expression than those seen at leukemia onset, suggesting that BCL-2-expressing blasts might be those escaping apoptosis in first-line treatments (Bensi et al., 1995; Testa and Riccioni, 2007; Kuusanmäki et al., 2020).